日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

转移性非小细胞肺癌患者一线免疫疗法(联合或不联合化疗)的真实世界疗效与临床试验结果比较:CORRELATE 研究

Peters, S; Salomonsen, R J-B; Diaz Perez, I; Shcherbakova, T; Wang, A; Cai, L; Sadow, S; Liu, S V

Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study

EGFR突变型非小细胞肺癌转化为小细胞肺癌患者的治疗与预后相关性:一项国际回顾性研究

Catania, C; Liu, S V; Garassino, M; Delmonte, A; Scotti, V; Cappuzzo, F; Genova, C; Russo, A; Russano, M; Bennati, C; Colantonio, I; Martini, S; Pino, M; Conforti, F; Pala, L; Minuti, G; Citarella, F; Olmetto, E; Esposito, A; Cascetta, P; Di Lello, A; De Pas, T

Validation of an AI-enabled exome/transcriptome liquid biopsy platform for early detection, MRD, disease monitoring, and therapy selection for solid tumors.

验证人工智能驱动的外显子组/转录组液体活检平台在实体瘤早期检测、微小残留病灶检测、疾病监测和治疗选择中的应用

Abraham J, Domenyuk V, Perdigones N, Klimov S, Antani S, Yoshino T, Heath E I, Lou E, Liu S V, Marshall J L, El-Deiry W S, Shields A F, Dietrich M F, Nakamura Y, Fujisawa T, Demetri G D, Barker A, Xiu J, Sacchetti D A, Stahl S, Hahn-Lowry R, Stark A, Swensen J, Poste G, Halbert D D, Oberley M, Radovich M, Sledge G W, Spetzler David B

Real-world survival of patients treated with taxane therapy after exposure to immunotherapy and platinum-based chemotherapy for advanced non-small-cell lung cancer without actionable mutations

对于无可靶向突变的晚期非小细胞肺癌患者,在接受免疫疗法和铂类化疗后,接受紫杉烷类药物治疗的患者的真实世界生存情况

Liu, S V; Hu, X; Chirovsky, D; Meng, W; Samkari, A

NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents

NRG1融合驱动肿瘤:生物学、检测以及阿法替尼和其他ErbB靶向药物的治疗作用

Laskin, J; Liu, S V; Tolba, K; Heining, C; Schlenk, R F; Cheema, P; Cadranel, J; Jones, M R; Drilon, A; Cseh, A; Gyorffy, S; Solca, F; Duruisseaux, M

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer

RET融合阳性非小细胞肺癌对选择性RET酪氨酸激酶抑制剂的耐药机制

Lin, J J; Liu, S V; McCoach, C E; Zhu, V W; Tan, A C; Yoda, S; Peterson, J; Do, A; Prutisto-Chang, K; Dagogo-Jack, I; Sequist, L V; Wirth, L J; Lennerz, J K; Hata, A N; Mino-Kenudson, M; Nardi, V; Ou, S-H I; Tan, D S-W; Gainor, J F

What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)

MASC 背后的秘密:在乳腺类似分泌性癌 (MASC) 中鉴定出 ETV6-NTRK3 后,恩曲替尼的临床反应和获得性耐药性

Drilon, A; Li, G; Dogan, S; Gounder, M; Shen, R; Arcila, M; Wang, L; Hyman, D M; Hechtman, J; Wei, G; Cam, N R; Christiansen, J; Luo, D; Maneval, E C; Bauer, T; Patel, M; Liu, S V; Ou, S H I; Farago, A; Shaw, A; Shoemaker, R F; Lim, J; Hornby, Z; Multani, P; Ladanyi, M; Berger, M; Katabi, N; Ghossein, R; Ho, A L

Identification of novel host cell binding partners of Oas1b, the protein conferring resistance to flavivirus-induced disease in mice

鉴定 Oas1b 的新型宿主细胞结合伙伴,Oas1b 是一种赋予小鼠对黄病毒诱发疾病抗性的蛋白质

S C Courtney, H Di, B M Stockman, H Liu, S V Scherbik, M A Brinton